This protocol relies on the provision of human surgical tissue. Ethical approval and informed patient consent were obtained prior to experimentation, and the study conformed with the principles outlined in the Declaration of Helsinki.
1. Collection of tissue and ex vivo wounding
2. Tissue fixation and cryosectioning
3. Laser capture microdissection
4. Quantification of differential gene expression
First amplification round | Second amplication round | ||||
First strand synthesis | First strand synthesis | ||||
Step | Temperature | Time | Step | Temperature | Time |
1 | 65 °C | 5 min | 1 | 65 °C | 5 min |
2 | 4 °C | hold | 2 | 4 °C | hold |
3 | 42 °C | 45 min | 3 | 25 °C | 10 min |
4 | 4 °C | hold | 4 | 37 °C | 45 min |
5 | 37 °C | 20 min | 5 | 4 °C | hold |
6 | 95 °C | 5 min | |||
7 | 4 °C | hold | Second strand synthesis | ||
Step | Temperature | Time | |||
Second strand synthesis | 1 | 95 °C | 2 min | ||
Step | Temperature | Time | 2 | 4 °C | hold |
1 | 95 °C | 2 min | 3 | 37 °C | 15 |
2 | 4 °C | hold | 4 | 70 °C | 5 min |
3 | 25 °C | 5 min | 5 | 4 °C | hold |
4 | 37 °C | 10 min | |||
5 | 70 °C | 5 min | In vitro transcription | ||
6 | 4 °C | hold | Step | Temperature | Time |
1 | 42 °C | 6 h | |||
In vitro transcription | 2 | 4 °C | hold | ||
Step | Temperature | Time | 3 | 37 °C | 15 min |
1 | 42 °C | 3 h | 4 | 4 °C | hold |
2 | 4 °C | hold | |||
3 | 37 °C | 15 min | |||
4 | 4 °C | hold |
Table 1: Amplification conditions.
5. Data interpretation
Following the protocol, a 48 h timepoint was chosen to generate representative results. The creation of the initial wound in surplus tissue from elective cosmetic surgery can be seen in Figure 2A where the excised wound is clearly visible. Haematoxylin and eosin staining confirms that this has generated a full thickness wound (Figure 2B). After 48 h, partial closure of the wound is visible under the light microscope (Figure 2C). Histological staining reveals the epithelial tongue that is progressing to heal the wound (Figure 2D), demonstrating that the ex vivo wound healing model is a valid proxy for in vivo wound healing.
After sectioning and staining with haematoxylin and eosin, the healing wound was visualized on the laser capture microdissection system and the wound area selected (Figure 3A). This area was completely excised using this method as can be seen in Figure 3B. RNA quality and purity was reasonable (analyzed by RNA integrity number (RIN); Figure 3C) – poor quality amplified RNA would have many peaks and troughs indicating multiple degradation products. Isolation of small tissue sections may yield RNA that is of a very low concentration that makes valid interpretation of qPCR difficult. Figure 3D demonstrates the variation in RNA concentration to be expected using this technique, with a range of 2.00 to 6.15 ng/mL. Importantly, even dilute samples were able to give robust CT values for both housekeeper (GAPDH) and skin-specific genes of interest (keratin 17; KRT17; Figure 3E), confirming the suitability of the technique for comparative transcriptomic studies.
Figure 1: Flow diagram of the complete technique to perform gene expression analysis on laser microdissected tissue from wounded skin. Tissue is wounded, allowed to heal in a tissue incubator and imaged (steps 1-6) before being cut into 7 μm sections using a cryostat (step 7). The region of interest (e.g. epithelial tongue) is identified and collected using laser capture microdissection (steps 8-9) and RNA isolated, purified and gene expression determined (steps 10-12). Please click here to view a larger version of this figure.
Figure 2: Ex vivo wound model. Human tissue was wounded by creating two parallel cuts and removing the tissue between to leave a uniform wounded area (A, light microscope, scale bar = 200 µm; B, haemoatoxylin and eosin staining, scale bar = 100 µm). The tissue was cultured in a standard tissue culture incubator at 37°C in 5% CO2 in air for 48 h (C, light microscope, scale bar = 200 µm; D, haematoxylin and eosin staining, scale bar = 100 µm). Arrow heads indicate epithelial tongue. Please click here to view a larger version of this figure.
Figure 3: Laser capture microdissection and gene expression. A. The region of interest (in this case, healed tissue) was identified using haematoxylin staining and collected using laser capture microdissection. B. The same region imaged after microdissection. Scale bars = 50 µm. C. Representative electropherogram of RNA that was isolated, amplified and quantified from the laser microdissected tissue. D. RNA concentration from collected tissue (n=24 samples). E. Reproducible detection of GAPDH and KRT17 expression using qPCR (n=13 samples, mean ± SEM). Please click here to view a larger version of this figure.
Arcturus RiboAmp PLUS kit | ThermoFisher Scientific | KIT0521 | RNA amplification kit |
Diffuser Caps 0.5mL | MMI | K10028161 | Laser capture microdissection caps; 50 pack |
Dulbecco’s Modified Eagle Medium (DMEM) | Sigma-Aldrich | D6046 | With 1000 mg/L glucose, L-glutamine, and sodium bicarbonate, liquid, sterile-filtered, suitable for cell culture |
Foetal Bovine Serum | Thermo Fisher Scientific | 10270106 | Cell culture supplement |
H&E Staining Kit Plus | MMI | K10028305 | Rnase-free haematoxylin and eosin staining kit |
High capacity cDNA reverse transcription kit | Applied Biosystems | 4368814 | Reverse transcription kit |
L-glutamine | Thermo Fisher Scientific | 25030149 | Cell culture supplement |
MembraneSlides | MMI | K10028153 | Laer capture microdissection slides; 5 per box |
Netwell Mesh Insert | Corning | 3479 | Cell culture insert |
Penicillin-Streptomycin-Fungizone | Thermo Fisher Scientific | 15070-063 | Cell culture supplement |
15290-026 | |||
OCT | Tissue-Tek Sakura | 4583 | Cryostat-compatible cutting medium |
PBS | Thermo Fisher Scientific | 10209252 | Five tablets per 100ml sterile water and then autoclaved for cell culture use |
RNeasy Micro Kit | Qiagen | 74004 | RNA extraction kit |
RNase Away | Sigma-Aldrich | 83931 | RNase spray |
Sterile blades | Scientific Laboratory Supplies | INS4974 | Tissue dissection implements |
Support Slide | MMI | K10028159 | Laser capture microdissection support slide, RNase-free |
Surgical scissors | Scientific Laboratory Supplies | INS4860 | Tissue dissection implements |
Surgical forceps | Scientific Laboratory Supplies | INS2026 | Tissue dissection implements |
SYBR Green Supermix | Applied Biosystems | 4344463 | Quantitative PCR mastermix |
The global prevalence Type 2 diabetes mellitus (T2DM) is escalating at a rapid rate. Patients with T2DM suffer from a multitude of complications and one of these is impaired wound healing. This can lead to the development of non-healing sores or foot ulcers and ultimately to amputation. In healthy individuals, wound healing follows a controlled and overlapping sequence of events encompassing inflammation, proliferation, and remodelling. In T2DM, one or more of these steps becomes dysfunctional. Current models to study impaired wound healing in T2DM include in vitro scratch wound assays, skin equivalents, or animal models to examine molecular mechanisms underpinning wound healing and/or potential therapeutic options. However, these do not fully recapitulate the complex wound healing process in T2DM patients, and ex vivo human skin tests are problematic due to the ethics of taking punch biopsies from patients where it is known they will heal poorly. Here, a technique is described whereby expression profiles of the specific cells involved in the (dys)functional wound healing response in T2DM patients can be examined using surplus tissue discarded following amputation or elective cosmetic surgery. In this protocol samples of donated skin are collected, wounded, cultured ex vivo in the air liquid interface, fixed at different time points and sectioned. Specific cell types involved in wound healing (e.g., epidermal keratinocytes, dermal fibroblasts (papillary and reticular), the vasculature) are isolated using laser capture microdissection and differences in gene expression analyzed by sequencing or microarray, with genes of interest further validated by qPCR. This protocol can be used to identify inherent differences in gene expression between both poorly healing and intact skin, in patients with or without diabetes, using tissue ordinarily discarded following surgery. It will yield greater understanding of the molecular mechanisms contributing to T2DM chronic wounds and lower limb loss.
The global prevalence Type 2 diabetes mellitus (T2DM) is escalating at a rapid rate. Patients with T2DM suffer from a multitude of complications and one of these is impaired wound healing. This can lead to the development of non-healing sores or foot ulcers and ultimately to amputation. In healthy individuals, wound healing follows a controlled and overlapping sequence of events encompassing inflammation, proliferation, and remodelling. In T2DM, one or more of these steps becomes dysfunctional. Current models to study impaired wound healing in T2DM include in vitro scratch wound assays, skin equivalents, or animal models to examine molecular mechanisms underpinning wound healing and/or potential therapeutic options. However, these do not fully recapitulate the complex wound healing process in T2DM patients, and ex vivo human skin tests are problematic due to the ethics of taking punch biopsies from patients where it is known they will heal poorly. Here, a technique is described whereby expression profiles of the specific cells involved in the (dys)functional wound healing response in T2DM patients can be examined using surplus tissue discarded following amputation or elective cosmetic surgery. In this protocol samples of donated skin are collected, wounded, cultured ex vivo in the air liquid interface, fixed at different time points and sectioned. Specific cell types involved in wound healing (e.g., epidermal keratinocytes, dermal fibroblasts (papillary and reticular), the vasculature) are isolated using laser capture microdissection and differences in gene expression analyzed by sequencing or microarray, with genes of interest further validated by qPCR. This protocol can be used to identify inherent differences in gene expression between both poorly healing and intact skin, in patients with or without diabetes, using tissue ordinarily discarded following surgery. It will yield greater understanding of the molecular mechanisms contributing to T2DM chronic wounds and lower limb loss.
The global prevalence Type 2 diabetes mellitus (T2DM) is escalating at a rapid rate. Patients with T2DM suffer from a multitude of complications and one of these is impaired wound healing. This can lead to the development of non-healing sores or foot ulcers and ultimately to amputation. In healthy individuals, wound healing follows a controlled and overlapping sequence of events encompassing inflammation, proliferation, and remodelling. In T2DM, one or more of these steps becomes dysfunctional. Current models to study impaired wound healing in T2DM include in vitro scratch wound assays, skin equivalents, or animal models to examine molecular mechanisms underpinning wound healing and/or potential therapeutic options. However, these do not fully recapitulate the complex wound healing process in T2DM patients, and ex vivo human skin tests are problematic due to the ethics of taking punch biopsies from patients where it is known they will heal poorly. Here, a technique is described whereby expression profiles of the specific cells involved in the (dys)functional wound healing response in T2DM patients can be examined using surplus tissue discarded following amputation or elective cosmetic surgery. In this protocol samples of donated skin are collected, wounded, cultured ex vivo in the air liquid interface, fixed at different time points and sectioned. Specific cell types involved in wound healing (e.g., epidermal keratinocytes, dermal fibroblasts (papillary and reticular), the vasculature) are isolated using laser capture microdissection and differences in gene expression analyzed by sequencing or microarray, with genes of interest further validated by qPCR. This protocol can be used to identify inherent differences in gene expression between both poorly healing and intact skin, in patients with or without diabetes, using tissue ordinarily discarded following surgery. It will yield greater understanding of the molecular mechanisms contributing to T2DM chronic wounds and lower limb loss.